DNDildora Abdumalikovna Nabieva

Dildora Abdumalikovna Nabieva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dildora Abdumalikovna Nabieva has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eurasian Consensus of Rheumatologists on the diagnosis and treatment of systemic lupus erythematosus

    by G. A. Togizbaev, Ch. T. Baimukhamedov, B. G. Issayeva, Zh. E. Omarbekova, G. M. Koylubaeva, O. V. Lobanchenko, N. A. Martusevich, K. A. Chizh, S. M. Shukurova, A. A. Haroyan, et al.

    A group of leading rheumatologists from the Commonwealth of Independent States (CIS) countries has prepared clinical guidelines for the diagnosis, treatment, and monitoring of systemic lupus erythematosus. These clinical guidelines are based on the recommendations of the national rheumatology associations of the CIS countries, the international guidelines of the European Alliance of Associations for Rheumatology, and the American College of Rheumatology. These guidelines are intended for a wide range of specialists in the CIS countries, including rheumatologists and general practitioners.

  • Open Access

    Investigation of Hepatoprotective and Antidepressant Activity of Oil Extracted from the Iceland Plant in Experimental Animals under Study Conditions

    by Ikhtiyor Ikromovich Latipov, Dildora Abdumalikovna Nabieva, Miyassar Babakulovna Dzhabbarova, Ozodzhon Ilkhomovich Ergashov, Tokhir Erkiniy Rakhimzoda, Shukhrat Farkhodovich Ramazonov, Tolmas Tolibovich Khamroev

    The increased incidence of mental and emotional disorders against the background of ChLD, leading to disability and death due to its severe complications, in turn, leads to a further exacerbation of the existing problem. The high prevalence of depressive states in patients with ChLD compared with healthy people and the hepatotoxicity of existing antidepressants make it imperative to search for hepatoprotectors and antidepressants with a less toxic natural base. In this regard, the main purpose of the presented manuscript is to determine the hepatoprotective and antidepressant activity of the vegetable oil of Iceland in the study conditions. Studies to detect hepatoprotective activity were conducted on white rats and ChTLD was caused by oral administration of 500 mg/kg of pratacetamol and 1 ml of 40% ethanol for two weeks. On the other hand, the hepatoprotective activity of the test substance was assessed by blood biochemical parameters, the amount of bile secretion and its effect on its composition, and the antidepressant activity was realized in white mice using methods C. Hall, R. Porsolt and L. Steru. In the conducted studies, IVO was studied in doses of 100; 150 and 200 mg/kg, which showed high activity in stabilizing biochemical parameters disrupted by chronic administration of toxic substances, normalizing the excretion of bile and its components. It was found that the vegetable oil studied for this activity showed pronounced activity compared to the control dose and lower activity compared to the dose of phosphogliv 50 mg/kg, while apkosul showed similar activity compared to the dose of 100 mg/kg. In addition, the experimental animals showed clear depressive activity due to improved motor and search activity, increased forced swimming time and decreased immobilization time, and in terms of this activity, the comparative drug is not inferior to the studied dose of fluoxetine 10 mg/kg. The results obtained on the basis of research, in turn, dictate the need for large-scale physico-chemical studies based on this vegetable oil in order to obtain separately bioactive phytocomponents for the initial determination of their components. However, structural studies of this vegetable oil may lead to a further expansion of the range of PhTS.

  • Open Access

    Eurasian recommendations for the diagnosis and treatment of primary osteoarthritis (2025). League of Eurasian Rheumatologists (LEAR)

    by V. I. Mazurov, A. M. Lila, G. A. Togizbayev, H. T. Mirakhmedova, G. M. Koilubaeva, L. I. Alexeeva, E. A. Taskina, S. M. Nurgalieva, D. A. Nabiyeva, A. V. Naumov, et al.

    These guidelines represent the official 2025 recommendations of the League of Eurasian Rheumatologists (LEAR) for the diagnosis and management of primary osteoarthritis. The recommendations were developed with participation of leading experts in Russia, Kazakhstan, Kyrgyzstan, and Uzbekistan.


  • Open Access

    Consensus Statement on the Management of Patients With Asymptomatic Hyperuricemia in General Medical Practice

    by Oksana M. Drapkina, Vadim I. Mazurov, Martynov I. Martynov, Evgeny L. Nasonov, Sergey A. Saiganov, Aleksander M. Lila, Roman A. Bashkinov, Irina N. Bobkova, Chokan T. Baimukhamedov, Inna Z. Gaydukova, et al.

    Hyperuricemia is a condition characterized by an increase of serum uric acid level above 360 µmol/L. It is known that high serum uric acid levels are not only the condition for the etiopathogenesis of gout but also an important risk factor for the development and progression of cardiovascular diseases, kidney and liver pathologies, type 2 diabetes, and others. This makes hyperuricemia a relevant issue in general therapeutic practice. Despite extensive evidence on the negative role of hyperuricemia in many internal organ diseases, the management strategy for patients with asymptomatic hyperuricemia in real clinical practice remains a subject of debate. This resolution represents an interdisciplinary consensus of experts from Commonwealth of Independent States, based on current evidence-based medicine data and proprietary registries. The proposed algorithm emphasizes the importance of a personalized approach to the treatment of hyperuricemia, taking into account the severity of comorbid conditions and the level of cardiovascular risk. Step-by-step recommendations are provided for general practitioners, family doctors, and a wide range of specialists in both non-pharmacological and pharmacological urate-lowering therapy. These guidelines aim to improve the quality of medical care for patients at high risk of socially significant diseases occurring together with asymptomatic hyperuricemia.


  • Open Access

    Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice

    by O. M. Drapkina, V. I. Mazurov, A. I. Martynov, E. L. Nasonov, S. A. Saiganov, A. M. Lila, R. A. Bashkinov, I. N. Bobkova, Ch. T. Baimukhamedov, I. Z. Gaidukova, et al.

    Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике


  • Open Access

    Multimorbidity in osteoarthritis and pleiotropic effects of slow-acting symptomatic drugs. Resolution of the multidisciplinary International Expert Council

    by V. I. Mazurov, A. M. Lila, L. I. Alekseeva, Ch. T. Baymukhamedov, B. G. Isaeva, D. A. Iskra, M. Yu. Karimov, H. T. Mirakhmedova, A. M. Mkrtumyan, D. A. Nabieva, et al.

    In recent decades, the prevalence of osteoarthritis (OA), one of the most disabling diseases, has increased worldwide, which imposes a significant burden on society. At the international multidisciplinary meeting, experts of various specialties (rheumatology, neurology, endocrinology, geriatrics, rehabilitation, traumatology and orthopedics) from Russia, Uzbekistan, and Kazakhstan discussed the importance of an individualized approach to the treatment of patients with OA, taking into account comorbidities, identified the most important and common clinical phenotypes of the disease, discussed known symptom- and structure-modifying effects of a combination of glucosamine and chondroitin sulfate, and new data on additional (pleiotropic) effects of these drugs that may have a positive impact on the course of comorbid diseases and conditions. The resolution of the Expert Council summarizes the results of the discussion and focuses on issues that are important for the further development of therapeutic approaches and recommendations for the management of such patients.